• News
  • SAN DIEGO
  • BioTech

FDA accepts NDA submission for carbamazepine IV

Ligand Pharmaceuticals Inc.'s Captisol licensee Lundbeck LLC announced that the FDA has accepted for review a new drug application for its investigational therapy intravenous carbamazepine.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11119 N. Torrey Pines Rd. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
108.26
  0.48  
+ 0.45%
342,625,000
109.95
41.99

Insider Trade Data

Date Insider Shares Type Value
07/13/2015 Berkman, Charles S 15,067 Exchange $231,787
07/13/2015 Berkman, Charles S 15,067 Exchange $231,787
07/10/2015 Berkman, Charles S 14,067 Sell $1,394,610
07/10/2015 Berkman, Charles S 14,067 Sell $1,394,610
06/29/2015 Foehr, Matthew W 40,046 Exchange $399,259

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!